macroglobulinemia International prognostic scoring system for Waldenstrom's

摘要: ABSTRACT Recently, many new drugs have been developed for the treatment of Waldenstrom’s macroglobulinemia (WM). In order to optimize according prognosis and facilitate comparison trials we an international scoring system WM (ISSWM) in a series 587 patients with clearly defined criteria diagnosis initiation treatment. With median follow-up 64 months, survival after was 87 months. Five adverse covariates were identified: age >65 years, hemoglobin 11·5 g/dL, platelet count 100 x 10 9 /L, s2-microglobulin >3 mg/L serum monoclonal protein concentration >7.0 g/dL. Low risk (27% patients) presented 1 characteristic 65 intermediate (38%) 2 characteristics or only years high (35%) >2 characteristics. Five-year rates 87%, 68% 36% respectively (p alkylating agent, purine analogue. Thus, combination age, s2-microglobulin, blood counts may provide means design risk-adapted studies. However, independent validation biological markers enhance its significance.